Evidence map›Paper›PMID 30143913›Full record

ArticleInflammopharmacology2019

Melatonin ameliorates TNBS-induced colitis in rats through the melatonin receptors: involvement of TLR4/MyD88/NF-κB signalling pathway.

Mohsen Chamanara, Amir Rashidian, Shahram Ejtemaei Mehr, Ahmad-Reza Dehpour, Reza Shirkohi, Reyhaneh Akbarian, Alireza Abdollahi, Seyed-Mahdi Rezayat

Abstract read
PubMed Publisher
In one paragraph

Article in Inflammopharmacology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.

0numbers the graph read from it
0cells of the map it votes in
29citing papers in PubMed
2.9field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

29 citing papers in PubMed, 73 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Melatonin, an Antitumor Necrosis Factor Therapy.Journal of pineal research · 2025
    Review
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Ethyl acetate extract ofFrontiers in pharmacology · 2023
    Article
  11. Review
  12. Review
  13. Review
  14. Article
  15. Animal Models and Pathogenesis of Ulcerative Colitis.Computational and mathematical methods in medicine · 2022
    Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Mohsen ChamanaraDepartment of Pharmacology, School of Medicine, Tehran University of Medical Sciences, P.O. Box 13145-784, Tehran, Iran.
Amir RashidianDepartment of Pharmacology, School of Medicine, Tehran University of Medical Sciences, P.O. Box 13145-784, Tehran, Iran.
Shahram Ejtemaei MehrDepartment of Pharmacology, School of Medicine, Tehran University of Medical Sciences, P.O. Box 13145-784, Tehran, Iran.
Ahmad-Reza DehpourDepartment of Pharmacology, School of Medicine, Tehran University of Medical Sciences, P.O. Box 13145-784, Tehran, Iran.
Reza ShirkohiCancer Research Center, Cancer Institute of Iran, Tehran University of Medical Sciences, Tehran, Iran.
Reyhaneh AkbarianDepartment of Pharmacology, School of Medicine, Tehran University of Medical Sciences, P.O. Box 13145-784, Tehran, Iran.
Alireza AbdollahiDepartment of Pathology, Imam Hospital, Tehran University of Medical Sciences, Tehran, Iran.
Seyed-Mahdi RezayatDepartment of Pharmacology, School of Medicine, Tehran University of Medical Sciences, P.O. Box 13145-784, Tehran, Iran. Rezayat@tums.ac.ir.
Tehran University of Medical Sciences · IRMotamed Cancer Institute · IR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimThe aim of the present study is to investigate the anti-inflammatory effect of melatonin in trinitrobenzene sulfonic acid (TNBS)-induced rat colitis through the inhibition of Toll-like receptor 4 (TLR4)/nuclear factor kappa B (NF-κB) signalling pathway and activation of melatonin receptor.

methodsColitis was induced in Wistar rats by administration of 100 mg/kg TNBS dissolved in 0.25 ml of 50% ethanol solution using a flexible plastic rubber catheter into the colon via the anus. This resulted in incidence of colitis on the first day, and all treatments were conducted for 10 days after induction of colitis. Melatonin was administered intraperitoneally (i.p.) at doses of 1, 5, and 10 mg/kg/day. Luzindole (non-selective MT1/MT2 receptor antagonist) was administered i.p. at dose of 5 mg/kg/day 15 min prior to melatonin injection. During the experiment, animals were monitored for the appearance of diarrhoea, body weight loss, and rectal bleeding. Myeloid peroxidase enzyme and tumour necrosis factor-α (TNF-α) activities were detected by immunohistochemistry. The protein expression level of TLR4, myeloid differentiation factor 88 (MyD88), NF-κB p65, and inhibitor of kappa B (I-κB) were detected by western blotting analysis.

resultsTreatment with melatonin improved weight loss, mucosal, and histological damage compared with TNBS group. In addition, melatonin decreased TNBS-induced up-regulation of TLR4, MyD88, and NF-κB p65, and increased down-regulation of I-κB proteins. On the other hand, the administration of luzindole resulted in the inhibition of melatonin effects.

conclusionsIt seems that the inhibition of TLR4/NF-κB signalling pathway may mediate the anti-inflammatory effects of melatonin in TNBS-induced rat colitis.

Indexed as

AnimalsColitisColonDown-RegulationIntestinal MucosaMaleMelatoninMyeloid Differentiation Factor 88NF-kappa BRatsRats, WistarReceptors, MelatoninSignal TransductionToll-Like Receptor 4Trinitrobenzenesulfonic AcidUp-RegulationMelatoninMyd88 protein, ratMyeloid Differentiation Factor 88NF-kappa BReceptors, MelatoninTlr4 protein, ratToll-Like Receptor 4Trinitrobenzenesulfonic AcidMelatoninTLR4/NF-κB signalling pathwayTNBSUlcerative colitis

Identifiers

PMID30143913
OpenAlexW2888341140

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.